News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2024
June 2024
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Does the blast percentage in NPM1m mutated myeloid malignancies matter?
Jun 27, 2024, 19:08

Does the blast percentage in NPM1m mutated myeloid malignancies matter?

Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, shared on X:

“Does the blast percentage in NPM1m mutated myeloid malignancies matter? Some publications supporting that the disease behaves like AML even when blasts < 20%.”.

Anand Patel

Read further.
Source: Anand Patel/X

Anand Patel cancer myeloid malignancies OncoDaily Oncology
Societies
Jun 28, 2024, 13:42
NEST Trial highlighted by Myriam Chalabi
Insight
Jun 28, 2024, 13:41
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Societies
Jun 28, 2024, 13:32
Updated results from the TRANSMET trial at ESMOGI24
Blog
Jun 28, 2024, 13:17
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
Insight
Jun 28, 2024, 13:15
The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO
Insight
Jun 28, 2024, 13:09
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Insight
Jun 28, 2024, 13:00
Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer
Insight
Jun 28, 2024, 12:53
Myeloma Paper of the Day, June 28th, suggested by Robert Orlowski
Insight
Jun 28, 2024, 12:50
AI model may yield better outcomes for prostate cancer - UCLA Health
Blog
Jun 28, 2024, 12:46
The partnership between UICC and Tradition Genève 1959 will enable access to early breast cancer detection services for women
Blog
Jun 28, 2024, 12:37
Devika Das: A whole new Pandora’s box of toxicities with the advent of check point inhibitors
Blog
Jun 28, 2024, 12:35
Over €14 M to Advance Development of Tacalyx's Cancer Therapeutics Targeting TACAs